The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
Researchers warn that it is "vital" to reduce PFAS exposure for expecting mothers, given long-term health risks for unborn children.
New GLP-1 warnings will urge users to inform their doctors before surgery if they are taking the diabetes and weight loss drugs.
Court will examine general causation, along with other “cross cutting” issues, before selecting any individual Ozempic gastroparesis lawsuits for trial workup.
Research indicates women have seen an increased risk of heart disease, stroke and type 2 diabetes in recent decades, correlating with an increased use of birth control pills.
Lawsuit indicates that the gastroparesis diagnosis from Ozempic was confirmed after plaintiff underwent a gastric emptying test, which is evidence not present in many other claims in the litigation.
MiniMed insulin pumps have a history of problems that have led to numerous recalls over the last decade, following reports of over or under delivery of insulin.
Novo Nordisk allegedly knew for years about the risk that Ozempic and Rybelsus may cause ileus and other severe gastrointestinal side effects, but failed to warn doctors or patients.
Side effects of Mounjaro caused cyclical vomiting that required emergency medical treatment, lawsuit claims.
Kentucky woman claims Ozempic caused stomach paralysis, which resulted in the need for emergency medical treatment and left her with permanent injuries.
